Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Avenzo Therapeutics has raised $60.0M in total funding. The most recent round was Series B. The last funding was announced in September 2025.
Avenzo Therapeutics's investors include OrbiMed, New Enterprise Associates, Foresite Capital, SR One, Longwood Fund.
Avenzo Therapeutics is headquartered in San Diego, United States.
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Avenzo Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Avenzo Therapeutics — Funding & Investors." VCBacked, September 4, 2025, https://www.vcbacked.co/company/avenzo-therapeutics. Accessed October 2, 2026.
VCBacked. (2025). Avenzo Therapeutics — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/avenzo-therapeutics
{{cite web |title=Avenzo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/avenzo-therapeutics |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated